Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Accumulated Expenses (2022 - 2024)

Universe Pharmaceuticals' Accumulated Expenses history spans 3 years, with the latest figure at $49.5 million for Q3 2024.

  • On a quarterly basis, Accumulated Expenses rose 1724.48% to $49.5 million in Q3 2024 year-over-year; TTM through Sep 2024 was $49.5 million, a 1724.48% increase, with the full-year FY2024 number at $49.5 million, up 1724.48% from a year prior.
  • Accumulated Expenses hit $49.5 million in Q3 2024 for Universe Pharmaceuticals, up from $2.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for UPC hit a ceiling of $49.5 million in Q3 2024 and a floor of $2.5 million in Q3 2022.
  • Historically, Accumulated Expenses has averaged $18.2 million across 3 years, with a median of $2.7 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: rose 6.79% in 2023 and later surged 1724.48% in 2024.
  • Tracing UPC's Accumulated Expenses over 3 years: stood at $2.5 million in 2022, then grew by 6.79% to $2.7 million in 2023, then surged by 1724.48% to $49.5 million in 2024.
  • Business Quant data shows Accumulated Expenses for UPC at $49.5 million in Q3 2024, $2.7 million in Q3 2023, and $2.5 million in Q3 2022.